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The application of massively parallel sequencing (MPS)
platforms has begun to revolutionize our understanding
of the immense variation in the human genome and the
complexity that can underlie genetic susceptibility to
disease. The utility of exome capture MPS through the
identification of genes for rare Mendelian disorders
based on analysis of only a few individuals has been elo-
quently demonstrated. Common diseases such as breast
cancer present substantially increased complexity in
terms of locus, allelic and phenotypic heterogeneity, as
well as complex relationships between genotype and
phenotype (reduced penetrance, phenocopies etc.). With
careful consideration of study design [1], thoughtful
selection of families from our international resources
(whole exome sequencing of two highly selected affected
members of multiple-case breast cancer families), and a
well-developed strategy (analytical pipeline) for distin-
guishing the few true breast cancer susceptibility genes
from the many genes that have rare genetic variants that
could plausibly alter protein function, we are advancing
a large program of work aimed at identifying the major-
ity of the “missing heritability” of breast cancer.
Our early findings demonstrate that:
1) despite very plausible biological roles, some genetic
variants in some genes predicted to be damaging by
SIFT and Polyphen2 do not appear to be associated
with breast cancer risk [2].
2) application of our strategy can identify new breast
cancer susceptibility genes. During the early conduct of
this program, we identified a family with a protein
truncating mutation in a gene involved in DNA repair.
Follow-up has included mutation screening of:
a) youngest affected members of 250 multiple-case
breast cancer families,
b) cases and controls participating in Australian popu-
lation-based studies of breast cancer (ABCFS and
MCCS)
c) cases and controls in an international population-
based case-control-family resource (BCFR)
To date, these analyses have identified 6 families with
frameshift or evolutionarily unlikely missense mutations
in this gene. Features of these families include multiple-
cases of early-onset female breast cancer with some
potentially other interesting features such as early-onset
male breast cancer and pancreatic cancer. These muta-
tions have not been found in approximately 3000 unaf-
fected population-based controls without a family
history of breast cancer.
We are continuing to expand our dataset to include
the exome sequences of further families and coordinat-
ing the follow-up of candidate genes using appropriate
MPS platforms and as founding partners of a newly
formed international consortium of breast cancer exome
sequencing researchers.
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